

OFFICE OF ACQUISITIONS
NATIONAL CANCER INSTITUTE

REQUEST FOR PROPOSAL NUMBER: N01CN55003-47

Amendment No.: 7

Date of Issuance: 03/05/2015

The above numbered Request For Proposal (RFP) is amended as set forth below. The hour and date specified for receipt of Offerors remains unchanged: 3/30/15 2:00PM EST.

Offerors MUST acknowledge receipt of the amendment prior to the hour and the date specified in the solicitation or as amended, by separate letter, telegram, or Electronic Mail which includes a reference to the RFP and Amendment number(s). For your convenience, the Proposal Intent Response Form is provided in SECTION J - List of Attachments of this RFP, for this purpose.

FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERORS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.

This Amendment provides responses to questions received on 3/2/15 and 3/3/15, as stated below:

Inquiry 1 received 3/2/15 -

Question 1: Confirm that the initial budget is to lay the groundwork for preparing for [proposals] and execution of task orders which themselves are associated with specific budgets. I am guessing that this is why your team has asked for a response to the sample Task Order as a way to gauge costs for subsequent task orders.

Response 1: That is correct.

Question 2: Regarding the application and specifically describing our procurement capabilities, can we propose compounds and small molecule inhibitors that have been made in-house by our nationally-renowned Cancer Drug Discovery program? Our program has developed a number of new agents that are at various stages of development, including Phase 1 clinical trials in humans.

Response 2: The offeror should propose small molecule inhibitors with validated physiochemical properties, specificity, and *in vivo* characterization, including compound at the stage of clinical development.

Question 3: Would it be of interest to the program to also propose the possibility of doing follow up analyses using human and mouse organoid systems in addition to mouse modeling?

Response 3: The offeror could propose additional follow-up studies, which directly relate to animal models.

Inquiry 2 received 3/2/15 -

Question 1: Technical question related to the Sample Task Order: Is it appropriate to test the efficacy of Mdm2/MdmX inhibitors using xenograft models with cancer cells carrying alterations in Mdm2 or MdmX in the Sample Task Order?

Response 1: The offeror should use either carcinogen-induced or genetic-modified animal models. However, the offeror could add xenograft models as an appendix or attachment.

Inquiry 3 received 3/3/15 -

Question 1: Upon review of Solicitation N01-CN55003-47, the guidelines specify a page limitation of 120 pages. Does this limitation include pages for biosketches?

Response 1: Attachment 9, Additional Technical Proposal Instructions, page 2., states that the 120 page limit excludes the cover sheet, resumes and all appendices or attachments and the proposal for the sample task order.

END OF AMENDMENT 7.